Open-label, Combined Dose-finding (Phase I) and Efficacy-finding (Phase II) Study of RO5323441 in Combination With Bevacizumab for Patients With Recurrent Glioblastoma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Dose-Finding Part: Dose limiting toxicity
Day 28
No
Clinical Trials
Study Director
Hoffmann-La Roche
France: Ministry of Health
BP25389
NCT01308684
May 2011
April 2013
Name | Location |
---|